Phase Forward Introduces Phase Forward™ IRT 5.0 Interactive Response Technology Solution
News Oct 26, 2009
Phase Forward has announced a major new release of its Interactive Response Technology (IRT) solution, Phase Forward™ IRT 5.0. Based on best-in-breed technology gained in the company’s September 2008 acquisition of Clarix, Phase Forward IRT 5.0 gives managers direct control over clinical supply management and helps to provide assurance of supply availability at randomization.
Phase Forward IRT also offers a new integrated drug forecasting module for advanced global clinical trial supply management and a new, enhanced user interface to streamline navigation and consolidate workflow.
“Phase Forward IRT 5.0 is a major step forward in helping customers leverage the power of IRT technology to improve efficiency within clinical trial supply management and planning, a crucial factor in every trial’s success,” said Steve Rosenberg, senior vice president of products and services, Phase Forward. “This release is a key component of our integrated clinical research suite for end-to-end clinical trial management.”
The Phase Forward IRT 5.0 release introduces a new “smart system intelligence” feature that puts clinical supply managers in control, helping them effectively respond to sudden increases in new subjects at any point in the trial. On the basis of user-defined variables, the application will either automatically generate a supply order or notify the supply manager of a potential stock-out, ensuring that subject enrollment is not compromised by lack of study supplies.
The new integrated drug forecasting module gives managers pre-study planning tools to optimize trial supply strategies. During live trials the application links to trial data on demand, enabling managers to compare planning assumptions and forecasts with actual trial data, update supply demand assumptions as needed and modify manufacturing schedules to respond to new projections.
New user interface and dashboard views provide at-a-glance access to critical information, visual status alerts and filtering capabilities to guide users intuitively through tasks, consolidating workflow and helping to ensure that the most pertinent information stays paramount. The release also provides multilingual capabilities, including Japanese, to enable use across the global trial community.
Together, Phase Forward’s IRT and InForm™ GTM electronic data capture (EDC) solutions offer users a tightly integrated solution with a single, unified interface and seamless workflow, providing the total cost of ownership and single point of contact benefits inherent in a single vendor solution.
The Phase Forward IRT 5.0 solution and the optional forecasting module are immediately available.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.
Comments | 0 ADD COMMENT
World Congress on Clinical And Medical Microbiology
Sep 10 - Sep 11, 2018